HIV-1C in-House RNA-Based Genotyping Assay for Detection of Drug Resistance Mutations in Samples with Low-Level Viral Loads.
HIV-1C drug resistance testing
in-house genotyping
low-level viremia
samples
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
09
2022
accepted:
08
11
2022
entrez:
30
12
2022
pubmed:
31
12
2022
medline:
31
12
2022
Statut:
epublish
Résumé
Monitoring HIV-1 drug resistance mutations (DRM) in treated patients on combination antiretroviral therapy (cART) with a detectable HIV-1 viral load (VL) is important for the selection of appropriate cART. Currently, there is limited data on HIV DRM at low-level viremia (LLV) (VL 401-999 copies/mL) due to the use of a threshold of VL ≥1000 copies/mL for HIV DRM testing. We here assess the performance of an in-house HIV drug resistance genotyping assay using plasma for the detection of DRM at LLV. We used a total of 96 HIV plasma samples from the population-based Botswana Combination Prevention Project (BCPP). The samples were stratified by VL groups: 50 samples had LLV, defined as 401-999 copies/mL, and 46 had ≥1000 copies/mL. HIV pol (PR and RT) region was amplified and sequenced using an in-house genotyping assay with BigDye sequencing chemistry. Known HIV DRMs were identified using the Stanford HIV Drug Resistance Database. Genotyping success rate between the two groups was estimated and compared using the comparison of proportions test. The overall genotyping success rate was 79% (76/96). For VL groups, the genotyping success was 72% (36/50) at LLV and 87% (40/46) at VL ≥1000 copies/mL. Among generated sequences, the overall prevalence of individuals with at least 1 major or intermediate-associated DRM was 24% (18/76). The proportions of NNRTI-, NRTI- and PI-associated resistance mutations were 28%, 24%, and 0%, respectively. The most predominant mutations detected were K103N (18%) and M184V (12%) in NNRTI- and NRTI-associated mutations, respectively. The prevalence of DRM was 17% (6/36) at LLV and 30% (12/40) at VL ≥1000 copies/mL. The in-house HIV genotyping assay successfully genotyped 72% of LLV samples and was able to detect 17% of DRM amongst them. Our results highlight the possibility and clinical significance of genotyping HIV among individuals with LLV.
Identifiants
pubmed: 36582452
doi: 10.2147/IDR.S388816
pii: 388816
pmc: PMC9792565
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7565-7576Subventions
Organisme : FIC NIH HHS
ID : K43 TW012350
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-033558
Pays : United States
Organisme : CGH CDC HHS
ID : U01 GH000447
Pays : United States
Organisme : NHGRI NIH HHS
ID : U41 HG006941
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009610
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001911
Pays : United States
Informations de copyright
© 2022 Bareng et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in relation to this work.
Références
World J AIDS. 2013 Jun;3(2):71-78
pubmed: 25664219
J Hum Virol. 2000 Jan-Feb;3(1):27-34
pubmed: 10774804
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
J Virol Methods. 2004 Aug;119(2):73-8
pubmed: 15158587
New Microbiol. 2007 Jul;30(3):313-7
pubmed: 17802917
HIV Med. 2008 Oct;9(8):673-6
pubmed: 18557948
BMJ Open. 2021 Feb 16;11(2):e045373
pubmed: 33593788
J Clin Microbiol. 2016 Apr;54(4):1175
pubmed: 27016593
AIDS. 2002 Oct 18;16(15):2035-41
pubmed: 12370502
J Antimicrob Chemother. 2022 Apr 27;77(5):1385-1395
pubmed: 35229102
J Antimicrob Chemother. 2021 Sep 15;76(10):2659-2665
pubmed: 34278422
J Clin Virol. 2020 Nov;132:104657
pubmed: 33049643
Nucleic Acids Res. 2003 Jan 1;31(1):298-303
pubmed: 12520007
N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
AIDS. 2014 May 15;28(8):1125-34
pubmed: 24451160
J Virol. 2005 Aug;79(15):9625-34
pubmed: 16014925
AIDS Res Ther. 2021 Jan 6;18(1):1
pubmed: 33407664
Clin Infect Dis. 2019 Jan 7;68(2):177-187
pubmed: 30052811
AIDS. 2020 Aug 1;34(10):1559-1566
pubmed: 32675566
N Engl J Med. 2019 Aug 29;381(9):827-840
pubmed: 31329379
Antivir Ther. 2015;20(8):789-94
pubmed: 25945956
J Antimicrob Chemother. 2013 Jun;68(6):1400-5
pubmed: 23404192
J Antimicrob Chemother. 2016 May;71(5):1361-6
pubmed: 26929269
AIDS. 2010 Oct 23;24(16):2535-9
pubmed: 20651585
Postgrad Med J. 2003 Jan;79(927):36-42
pubmed: 12566550
AIDS. 2019 May 1;33(6):1073-1082
pubmed: 30946161
J Clin Microbiol. 2001 Apr;39(4):1254-7
pubmed: 11283037
Antimicrob Agents Chemother. 2012 Nov;56(11):5998-6000
pubmed: 22890763
Clin Infect Dis. 2014 Apr;58(8):1165-73
pubmed: 24429436
J Antimicrob Chemother. 2017 Jun 1;72(6):1769-1773
pubmed: 28333232
PLoS One. 2018 Jun 28;13(6):e0198246
pubmed: 29953436
Clin Infect Dis. 2008 Jul 15;47(2):266-85
pubmed: 18549313
AIDS. 2006 Mar 21;20(5):778-9
pubmed: 16514311
Jpn J Infect Dis. 2000 Oct;53(5):203-5
pubmed: 11135705
J Vis Exp. 2011 Sep 26;(55):
pubmed: 21968801
Clin Infect Dis. 2014 Apr;58(8):1174-5
pubmed: 24429434
Clin Infect Dis. 2014 Apr;58(8):1156-64
pubmed: 24429430